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Introduction
C-reactive protein (CRP) was first discovered in 1930 by Wil-
liam Tillet and Thomas Francis.48 In studying the blood of  
patients suffering from acute Streptococcus pneumonia in-
fection, it was found that the sera of  these patients formed 
a precipitin with an extract from the streptococcal bacterium. 
The extract was originally labelled Fraction C, and was later 
confirmed as a polysaccharide. Hence, as a result of  its re-
activity with the C-polysaccharide of  the Streptococcus cell 
wall, the ‘substance’ in the sera was named CRP.   
CRP ligand-binding is calcium dependent and binds with 
highest affinity to phosphocholine (PC), a constituent of  the cell 
membrane phospholipid, phosphatidylcholine. Under normal 
conditions phophatidylcholine is not exposed, however, once 
a cell has been damaged it becomes ‘accessible’ to CRP.7,52 
Synthesis and application
CRP synthesis was originally thought to be confined to the 
liver with no evidence supporting its production in cells oth-
er than hepatocytes.35 Jabs et al.15 have recently shown by 
real-time polymerase chain reaction (PCr) and immunohis-
tochemistry, that in response to stimulation with interleukin-
6 (IL-6), renal cortical tubular epithelial cells express CRP 
messenger ribonucleic acid (mRNA). Additional extrahepatic 
sites of  CRP synthesis/gene expression have been identified 
and include the epithelial cells of  the human respiratory tract 
and T-lymphocytes in culture.13,14 It is still generally accepted 
that the liver is the primary site of  de novo CRP production. 
CRP concentration can increase dramatically up to 1 000-
fold during the acute-phase response, and usually peaks 24 
- 48 hours after an initial acute inflammatory stimulus.20,34 
The half-life of  CRP is 19 hours and is independent of  the 
circulating concentration of  CRP.1 Hence, the primary factor 
determining the serum level of  CRP is the rate at which it is 
produced.1  
Normal systemic CRP levels are classified as less than 
5 mg/l with averages of  the sedentary/general population 
being estimated at approximately 2 mg/l.9 No difference in 
concentration exists between males and females, nor does 
CRP exhibit diurnal or seasonal variation.6,34 Serum levels 
are not affected by food intake, however, Ganapathi et al.10 
have shown that the CRP levels in human hepatoma cell 
lines are potentiated by caffeine. In addition, Church et al.5 
have shown that CRP levels are reduced through the use of  
a multivitamin over a 6-month period. 
Regardless of  the nature and location of  cellular/tissue 
damage, a non-specific, systemic acute-phase response is 
initiated. Although CRP has been identified as one of  the most 
prominent acute-phase proteins that allows for quantification 
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C-reactive protein (CRP) is an acute-phase reactant that 
increases in response to noxious stimuli that inevitably in-
duce cellular and/or tissue injury. The increased synthesis 
of  CRP occurs predominantly in the liver and peaks 24 - 
48 hours after the inciting stimulus. CRP forms an integral 
component of  innate immunity and serves primarily to rec-
ognise potential pathogens and damaged cells. It facilitates 
the removal of  these cells through opsonisation and acti-
vates the complement system. With increasing evidence 
supporting the classification of  artherosclerosis as inflam-
matory in nature, CRP has received considerable atten-
tion as a marker, and in some cases a contributor towards 
this cardiovascular disease. Traditionally, CRP has been 
measured within exercise studies to provide evidence that 
an acute-phase inflammatory response can or has been 
initiated. Although the elevation in CRP following exercise 
has largely been attributed to muscle damage, evidence is 
mounting to contest this premise. Participation in chronic 
exercise has been associated with a reduced risk of  cardi-
ovascular disease. Numerous studies have now shown an 
inverse relationship between physical activity levels and 
resting concentrations of  CRP. Thus, exercise may prove 
beneficial in lowering systemic inflammatory markers such 
as CRP, and consequently contribute towards preventing 
the progression of  inflammatory disorders.
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of  an inflammatory state, its elevation cannot differentiate 
between damaged tissues, hence its measurement and 
diagnostic value has been questioned.1 Thus, CRP is generally 
measured within a clinical setting to provide the physician 
with an indication of  disease activity, the effectiveness of  
pharmacological treatment and to determine if  intercurrent 
infections have manifested.1  Whilst an increase in CRP has 
generally been accepted as a response to an inflammatory 
‘condition’, Kushner has proposed that minor elevations of  
CRP are indicative of  biological ageing, a non-inflammatory 
condition.19 
Biological properties and functions of cRP
Recognition of pathogens and damaged cells
As part of  the acute-phase response, CRP levels may rise 
dramatically in order to facilitate non-specific immune func-
tions and assist with the repair process. The ability of  CRP 
to recognise disease-causing agents and damaged cells, 
and to mediate their removal, in conjunction with the fact that 
there exists an absence of  any documented human CRP de-
ficiency, highlights its crucial role in innate immunity. 
Within the human body millions of  cells die each day. 
Gershov et al.11 have proposed that a key role of  CRP is 
to facilitate the removal of  these cells. They reported that 
in addition to binding to lysed or permeabilised cells, CRP 
binds to the membranes of  intact apoptotic cells. The 
increased CRP was associated with enhanced phagocytosis 
of  the apoptotic cells and would thus contribute towards their 
clearance.
Opsonisation
On binding to various cell membrane surfaces or necrotic tis-
sue/debris, CRP then acts as an opsonin (from the Greek 
meaning ‘prepare food for’).2 Opsonisation involves coating 
of  the bacterial surface so that it can be recognised by other 
cells of  the immune system, specifically macrophages and 
neutrophils. Thus, opsonisation by CRP promotes the up-
take, and therefore removal of  these cells by phagocytes. 
activation and regulation of complement pathways (pro 
v. anti-inflammatory role)
In addition to the binding and subsequent opsonisation 
of  pathogens, CRP also serves to activate and modulate 
complement. CRP binds to C1q, the first component of  the 
complement cascade, and thereby initiates activation of  the 
classical pathway. The activation of  complement serves to 
enhance opsonisation and increase local inflammation. Ber-
man et al.3 have shown that although CRP activates the clas-
sical pathway of  complement, the terminal components (C5-
C9) known as the membrane attack complex (MAC) are not 
activated. This was in contrast to immunoglobulin G (IgG) 
and immunoglobulin M (IgM) activation of  the classical path-
way, which formed the MAC. The non-activation of  the MAC 
could be interpreted as an anti-inflammatory mechanism, 
since activation of  these terminal components has been as-
sociated with cellular injury and the release of  pro-inflamma-
tory cytokines. 
CRP also inhibits the alternate and lectin pathways 
of  complement through the recruitment of  factor H, a 
regulatory protein that promotes the degradation of  the 
C3 and C5 convertase.27 Thus CRP plays a dual pro and 
anti-inflammatory role in its regulation of  the complement 
system. 
The immunomodulating actions of  CRP and its pro and 
anti-inflammatory effects are not restricted to complement. 
Pue37 has shown that in response to lipopolysaccharide 
(LPS), the hosts’ peripheral blood mononuclear cells (PBMC) 
respond to CRP in a pro-inflammatory manner. However, 
once the CRP has moved into the tissue and reacts with 
macrophages, inflammation is suppressed through the 
inhibition of  interleukin-1b (IL-1b) and interleukin-1ra (IL-
1ra). Additional anti-inflammatory properties exhibited by 
CRP include the ability to decrease the expression of  cell 
adhesion molecule (L-selectin) in vitro, and reduce neutrophil 
superoxide production.9,54 
cRP and cardiovascular disease
A plethora of  studies have recently associated elevated se-
rum CRP levels with an increased risk of  developing cardio-
vascular disease (CVD). The increase in CRP is indicative 
of  an inflammatory response, and it is now widely accepted 
that atherosclerosis (the underlying cause of  most CVD) is a 
chronic inflammatory disorder.38 
Atherosclerosis is in part characterised by the deposition 
and accumulation of  lipids within arterial walls. These 
lesions can lead to ischaemia of  the brain, heart and 
peripheral tissues resulting in infarction.38 The oxidation of  
low-density lipoprotein (LDL) deposited on arterial walls is 
one of  a number of  factors contributing to what has been 
termed endothelial dysfunction,38 a hypothesis proposing 
that vascular injury, and hence inflammation, is induced by 
a number of  factors and possibly a combination thereof. 
Possible causes of  endothelial dysfunction are elevated 
and modified LDL, diabetes, genetic alterations, cigarette 
smoking, hypertension, elevated homocysteine, and 
infectious microorganisms (e.g. Chlamydia pneumoniae).38
Although substantial evidence from numerous studies 
has identified CRP as a marker of  CVD, increasing evidence 
is now implicating CRP as a risk factor directly involved in 
atherogenesis. Cermak et al.4 have reported that CRP 
induced a 75-fold increase in tissue factor (TF) procoagulant 
activity of  PBMC. It was suggested by the authors that 
the increase in monocyte TF expression (during infection/
necrosis) induced by CRP could contribute towards the 
development of  intravascular coagulation. This could 
arguably exacerbate the inflammatory state already present 
in ‘injured’ vessels. Nakagomi et al.29 also reported increases 
in PBMC TF concentrations in response to stimulation with 
CRP. The authors proposed that their findings shed light on 
the link between inflammation and coagulation, a connection 
‘which may contribute to the progression and outcome of  
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thrombotic events associated with atherosclerosis’. 
Using human umbilical vein endothelial cells, Pasceri et 
al.31 showed that CRP induced the expression of  monocyte 
chemoattractant protein-1 (MCP-1), a chemokine that 
attracts monocytes, natural killer (NK) cells and activates 
macrophages. The same group reported a CRP-induced 
increase in the expression of  intercellular adhesion molecule-
1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) 
in umbilical vein as well as coronary artery endothelial cells.32 
Inhibiting the expression of  cellular adhesion molecules 
has been shown to decrease phagocytic activity within 
atherosclerotic plaque.33 Pasceri et al.32 concluded that CRP 
is not just a marker of  inflammation, but rather that it may 
contribute to enhancing the progression of  inflammation/
atherosclerosis. 
In keeping with the role that CRP plays in contributing 
towards atherogenesis, Zwaka et al.55 demonstrated that CRP 
facilitates the phagocytosis of  native LDL by macrophages. 
The uptake of  LDL particles by macrophages results in the 
formation of  lipid peroxides, promotes the accumulation of  
cholesterol esters and eventually forms foam cells.38 Zwaka 
et al.55 suggested that the binding of  CRP to LDL within 
arterial walls might promote the onset of  arteriosclerosis. 
Nitric oxide (NO) plays an integral role in inflammation 
and immune regulation with lowered levels associated with 
adverse cardiac events. Verma et al.51 incubated endothelial 
cells with a concentration of  recombinant CRP known to 
predict adverse cardiovascular events. They measured the 
production of  NO and cyclic guanosine monophosphate 
(cGMP), the second messenger for NO. CRP elicited a 
dose-dependent, significant decrease in both NO and 
cGMP production. The authors concluded that the inhibitory 
effect that CRP exerts on NO production may facilitate the 
development of  cardiovascular disease. Similarly, Venugopal 
et al.50 investigated the effects that CRP had on endothelial 
nitric oxide synthase (eNOS) expression. Human aortic 
endothelial cells (HAEC) were incubated with recombinant 
CRP, and in a finding mirroring that of  Venugopal et al.,50 
eNOS and eNOS  mRNA protein levels were inhibited by 
CRP. This finding further supports the role of  CRP in the 
artherogenic process. 
Yasojima et al.53 used a reverse transcriptase-polymerase 
chain reaction to detect mRNA for CRP and complement 
proteins (C1-C9) in arterial and atherosclerotic plaque. They 
found evidence of  CRP as well as C1-C9 being synthesised 
within the arterial tissue of  10 postmortem cases.  In 
addition, mRNA and the respective proteins were elevated 
in atherosclerotic plaque. Since complement proteins have 
been associated with atherosclerotic plaque,39 and CRP is 
instrumental in potentiating local inflammation by binding 
with C1q it seems tenable that CRP may be involved in the 
pathogenesis of  atherosclerosis. 
Inflammation and exercise
It has been proposed that physical activity may serve as a 
model for studying the inflammatory response,41 and it is well 
established that an acute bout of  exercise may alter the circu-
lating levels of  a number of  pro-inflammatory cells including 
cytokines, acute-phase proteins and white blood cells.25,40,45 
Although there is general consensus regarding the induction 
of  an acute-phase inflammatory response following strenu-
ous, unaccustomed or prolonged bouts of  exercise, there is 
some degree of  uncertainty surrounding the precise stimuli 
responsible for this response. The majority of  authors have 
attributed the rise in inflammatory markers following physical 
activity to muscle damage. Evidence suggesting a possible 
role of  other factors/stimuli involved in inducing or exacer-
bating the inflammatory response following exercise may in-
clude haemolysis,21 endotoxaemia,16 and the production of  
reactive oxygen species.17 In addition, psychological stress, 
which may be more prevalent in elite athletes, has also been 
shown to cause an increase in pro-inflammatory cytokines.22 
Invariably, the mode, duration and intensity of  the exercise, 
as well as the subject’s level of  conditioning may all affect 
the magnitude of  the inflammatory response as well as rest-
ing concentrations of  inflammatory markers such as CRP. In 
keeping with this, King et al.18 have proposed that certain 
activities such as jogging, may be more beneficial in terms 
of  lowering inflammatory markers than other modes of  ex-
ercise.
As outlined above, CRP is involved in the activation of  
the classical pathway of  complement. Complement proteins 
are intimately involved in opsonisation, inflammation and cell 
lysis,28,42 and have been investigated in response to exercise 
of  varying mode and duration. Similar to CRP, the specific 
stimuli that upregulate complement proteins following 
exercise are controversial. However, as with CRP the resting 
concentrations of  selected complement proteins have been 
shown to be lower in athletes compared with sedentary 
individuals.30 More specifically, Nieman et al.30 reported lower 
levels of  C3 in athletes compared with sedentary controls. 
Interestingly, elevated C3 has recently been proposed as a 
marker to identify the progression of  atherosclerosis.46 
Effects of acute exercise on cRP 
The acute response of  CRP to physical activity has been 
published extensively, and the following section outlines a 
few of  the common findings. Increases in CRP have been 
observed following acute strenuous, prolonged bouts of  run-
ning,40 triathlon,16,47 bench stepping12 and anaerobic exer-
cise.26 Since eccentrically based exercise is more commonly 
associated with muscle damage, and CRP serves to bind 
damaged cells, it seems reasonable to assume that this type 
of  activity would be associated with pronounced elevations in 
CRP.  Results contradicting this assumption have been docu-
mented by Sorichter et al.44 and Malm et al.23 In both studies 
no significant elevations were observed for CRP following ec-
centric exercise (70 eccentric quadriceps contractions, and 
45 minutes of  downhill running respectively). These results 
suggest that elevations in CRP following exercise may not be 
solely due to muscle damage. Supporting this would be the 
findings of  Smith et al.43 In this study, CRP was significantly 
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(p < 0.04) elevated in 75% of  active-untrained subjects, 24 
hours after performing 60 minutes of  cycling at only 60% of  
maximal oxygen uptake. Similarly, Meyer et al.26 reported 
a significant (p = 0.02) increase in CRP 24 hours after 12 
trained males performed an anaerobic cycle ergometer test. 
Effects of chronic exercise on cRP
Pitsavos et al.36 used a sample of  891 men and 965 women 
older than 18 years, to determine the association of  leisure-
time physical activity on CRP and other inflammatory mark-
ers. The results revealed that CRP levels were 33% lower 
in the subjects who partook in high-physical activity levels 
compared with the sedentary group (high-physical activity 
was defined as expended calories > 7 kcal/min). Similarly, 
our laboratory has observed (unpublished data) that CRP 
resting levels are significantly lower in professional cyclists 
compared with active-untrained individuals. 
Tomaszewski et al.49 have reported ‘strikingly’ low CRP 
levels in runners. Sixty-seven male ultra-marathon runners 
were compared with sedentary individuals. They were all 
categorised into groups having a body mass index (BMI) 
less than 25 kg/m2 or greater than 25 kg/m2. Although non-
significant, the resting levels of  CRP were markedly lower 
in the marathon athletes compared with the controls. Even 
though there were differences in BMI, the CRP levels were 
similar amongst the marathon runners. Thus, the authors 
suggested that lowered CRP levels can be attained by intense 
regular exercise, and that this suppression is independent of  
adiposity levels. 
An interesting study by Mattusch et al.24 revealed changes 
in CRP concentration following 9 months of  training. Fourteen 
males (25 - 40 years) preparing for the Cologne Marathon 
provided blood samples before and after 9 months of  training 
for the event. The mean CRP concentration before the training 
began was 1.19 ± 1.63 mg/l for athletes, and after 9 months 
was significantly (p < 0.05) reduced to 0.82 ± 0.94 mg/l. 
There were no significant changes reported for the control 
group. The authors suggested that an anti-inflammatory 
effect is induced by endurance exercise performed over 9 
months. Similarly, Fallon et al.8 reported significantly (p < 
0.05) decreased levels of  CRP following 9 months of  soccer 
training in elite women, from a resting level of  2.68 (± 1.70 
mg/l) to 1.62 (± 1.32 mg/l). It was suggested that systemic 
anti-inflammatory mechanisms, associated with regular 
intense exercise were behind this finding. The proposed anti-
inflammatory effect of  chronic exercise suggests that physical 
activity may impart favourable health benefits on individuals 
by lowering CRP, a key role player in cardiovascular disease. 
In conclusion, CRP is an acute-phase protein that is 
upregulated in response to injury, infection or antigen 
exposure. CRP usually peaks 24 hours after exercise, and 
is more pronounced following longer more strenuous activity. 
The elevations in CRP following exercise have largely been 
attributed to muscle damage, however, it seems plausible 
that muscle damage does not have to be elicited by exercise 
in order for CRP to be elevated. The alterations in CRP are 
closely related to exercise-induced inflammatory sequelae 
and are more pronounced following activity that is longer or 
more aerobically challenging than exercise that is not. The 
supposed lower resting levels and adaptations associated 
with chronic physical activity may be more prominent following 
aerobic exercise although studies are lacking in which the 
effects of  resistance training are investigated. Numerous 
studies have shown that an inverse relationship exists 
between CRP and fitness levels, and that elevated CRP may 
be seen as a significant risk factor for CVD. In addition, resting 
CRP concentrations seem to be higher in sedentary versus 
active individuals. This supports the notion that exercise may 
‘downregulate’ systemic inflammatory markers and thus 
prove beneficial in opposing chronic inflammatory disorders 
such as cardiovascular disease. 
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